Objectives
The Cell Unit has the infrastructure to support cell-based tests and analyses for R&D in cancer, infectious diseases and various medical application areas, as well as support in various clinical studies such as the detection of residual diseases.
Areas of impact and applications in the field
Recent advances in bacterial and mammalian cell engineering include the development of cells that function in biological samples or within the body as minimally invasive diagnostics or theranostics for the real-time regulation of complex pathological conditions. Ex-vivo and in-vivo cell-based biosensors and therapeutics have been developed to target various diseases, including cancer.
A significant milestone in the field of theranostic cell engineering was the 2017 FDA approval of tisagenlecleucel, the first gene therapy approved in the USA. Considering the above, the Center will work on preclinical applications of mammalian sensing and drug delivery platforms and underlying biological designs that could lead to innovative cell diagnostics and therapeutics. In this process, it will be possible to detect rare cells, purify targeted cells and evaluate and monitor their responses/functions to the tested variable.
There is a growing need for novel, specific, sensitive, and compelling diagnostic and treatment procedures in infectious diseases. Synthetic systems and devices are evolving into robust tools for treating human infections. The advancement of synthetic biology provides efficient, accurate, and cost-effective platforms for detecting, preventing, and treating infectious diseases.
Services
– Cell Sorter
– Flow Cytometry
– Live Cell Analysis
– Fluorescence microscopy
